Background
The liver has a major role in the elimination and excretion of many
drugs, which can sometimes lead to chemical damage. Epidemiologic
studies have revealed that 1 in every 1000 individuals suffers from
drug-induced liver injury (DILI) (1); this damage can vary from mild lab
abnormalities to acute liver failure (2,3). Clopidogrel is an
anti-platelet medication from the Tinopyridine group which is
[commonly] used to prevent clot formation in coronary, cerebral and
peripheral vascular diseases and has led to decreased mortality and
reinfarction in patients with acute coronary syndrome. It is considered
relatively safe therapeutically, but liver injury has rarely been
reported after administration. Except two reported cases of cholestasis
[alone], liver injury due to clopidogrel has been in the form of a
hepatocellular or mixed cholestatic/hepatocellular pattern 94, 5, 6). In
this case report, an individual with severe liver injury due to
clopidogrel is assessed and there is also a literature review.